Table 1.
Parameter | Pseudoprogression | Treatment effect after radiosurgery | Radionecrosis | Tumor progression |
---|---|---|---|---|
Time to onset | 2–6 months after RT | 3–12 months after RT | 6–12 months after RT (but can be decades) | Any |
Characteristic imaging appearance | Contrast enhancement with FLAIR hyperintensity | Contrast enhancement with FLAIR hyperintensity | Contrast enhancement with FLAIR hyperintensity; ‘soap bubble’ or ‘Swiss cheese’ sign | Contrast enhancement with FLAIR hyperintensity |
Treatment | Observation with close follow-up | Observation with close follow-up | Steroids, bevacizumab, surgical resection | Tumor-directed therapy |
Usually symptomatic? | No | No | Yes | Yes |
MRI spectroscopy | Not clearly radionecrosis or tumor progression | Not clearly radionecrosis or tumor progression | Relatively less choline | Relatively less NAA and creatine; more choline and lactate |
Diffusion weighted imaging | Not clearly radionecrosis or tumor progression | Not clearly radionecrosis or tumor progression | Less restricted diffusion (lower signal) | More restricted diffusion (higher signal) |
Dynamic contrast imaging | Relatively low mean cerebral blood volume compared with true tumor progression | Relatively low mean cerebral blood volume compared with true tumor progression | Relatively low mean cerebral blood volume compared with true tumor progression | Relatively high mean cerebral blood volume |
FLAIR: Fluid attenuated inversion recovery; RT: Radiation therapy.